catalent (ctlt) inks deal for nasal spray for opioid overdoses. catalent inc. ctlt signed a commercial supply agreement with harm reduction therapeutics. per the agreement terms catalent will manufacture harm reduction therapeutics&rsq

bronstein gewirtz & grossman llc notifies catalent inc. (ctlt) investors of class action and to actively participate. new york march 24 2023 (globe newswire) -- attorney advertising-- bronstein gewirtz &. grossman llc notifies investors that a clas

harm reduction therapeutics and catalent sign commercial supply agreement for naloxone nasal spray to reverse opioid overdoses. harm reduction therapeutics a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by

catalent (ctlt) inks deal for new & effective drug delivery. catalent ctlt announced that it entered a licensing agreement with india-based biotech, bhami research laboratory ("brl"), to help enable the subcutaneous delivery of high-co

shareholder alert: pomerantz law firm investigates claims on behalf of investors of catalent, inc. - ctlt.

new york, march 20, 2023 (g

catalents (ctlt) tie-up to accelerate clinical trial timelines. catalent inc. ctlt recently announced its successful formulation design and clinical-phase manufacturing collaboration with grü.nenthal for an orally dosed small molec

rosen a respected and leading firm encourages catalent inc. investors with losses in excess of $100k to secure counsel before important deadline in securities class action – ctlt. ) between august 30 2021 and october 31 2022 both dates inclusive (the cl

guru fundamental report for ctlt - peter lynch. below is valideas guru fundamental report for catalent inc (ctlt). of the 22 guru strategies we follow ctlt rates highest using our p/e/growth investor model based on the published strategy of pet

heres why you should retain catalent (ctlt) stock for now. catalent inc. ctlt is well-poised for growth in the coming quarters courtesy of its product and service launches over the past few months. the optimism led by a solid second-qu

validea guru fundamental report for ctlt - 2/27/2023. below is valideas guru fundamental report for catalent inc (ctlt). of the 22 guru strategies we follow ctlt rates highest using our p/e/growth investor model based on the published strategy

wednesday sector laggards: healthcare financial. in afternoon trading on wednesday healthcare stocks are the worst performing sector not showing much of a gain. within the sector charles river laboratories international inc. (symbol: crl) a

validea daily guru fundamental report for ctlt - 2/13/2023. below is valideas daily guru fundamental report for catalent inc (ctlt). of the twelve guru strategies we follow ctlt rates highest using our p/e/growth investor model based on the pub

blackrock cuts stake in catalent (ctlt). fintel reports that blackrock has filed a 13g/a form with the sec disclosing ownership of 13.79mm shares of catalent inc (ctlt).

validea daily guru fundamental report for ctlt - 2/7/2023. below is valideas daily guru fundamental report for catalent inc (ctlt). of the twelve guru strategies we follow ctlt rates highest using our p/e/growth investor model based on the publ

catalent reports mixed q2 earnings. reaffirms fy23 guidance.

catalent (ctlt) surges on rumors of acquisition by danaher. shares of catalent ctlt gained 19.5% on monday on rumors of a potential acquisition by a life sciences company &mdash. danaher dhr. the ctlt stock started its upward journey d

catalent (ctlt) q2 earnings lag estimates revenues top. catalent inc. ctlt reported second-quarter fiscal 2023 adjusted earnings per share (eps) of 67 cents down 27.9% year over year. the bottom line missed the zacks consensus estimate

catalent (ctlt) misses q2 earnings estimates. catalent (ctlt) came out with quarterly earnings of $0.67 per share missing the zacks consensus estimate of $0.72 per share. this compares to earnings of $0.90 per share a year ago. these f

s&p 500 movers: tsn ctlt. in early trading on monday shares of catalent topped the list of the days best performing components of the s&.p 500 index trading up 24.5%. year to date catalent registers a 55.0% gain.

danaher shows interest in acquiring catalent valued at significant premium: report. ) has reportedly expressed interest in acquiring the contract manufacturer). according to the sources the recent moves by the life science firm valued catalent at a sig

earnings outlook for catalent. ) is set to give its latest quarterly earnings report on tuesday 2023-02-07. here'.s what investors need to know before the announcement. analysts estimate that catalent will report an catalent s will hope to hear the

catalent (ctlt) expected to beat earnings estimates: what to know ahead of q2 release. the market expects catalent (ctlt) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended d

validea daily guru fundamental report for ctlt - 1/25/2023. below is valideas daily guru fundamental report for catalent inc (ctlt). of the twelve guru strategies we follow ctlt rates highest using our p/e/growth investor model based on the pub

tuesday sector laggards: healthcare energy. the worst performing sector as of midday tuesday is the healthcare sector showing a 1.2% loss. within that group catalent inc (symbol: ctlt) and 3m co (symbol: mmm) are two large stocks that are l

catalent (ctlt ) presents at 41st annual healthcare conference - slideshow.

acorda strikes new global supply deal with catalent for its inhalation powder inbrija.

catalent to make sarepta therapeutics muscle wasting gene therapy under supply deal.